Latest Period
Q2 2026
Security Snapshot
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) Institutional Ownership
CUSIP: 61225M102
13F Institutional Holders and Ownership History from Q2 2021 to Q2 2026
Institutions Reporting
193
Shares (Excl. Options)
92,669,378
Price
$24.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GLUE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 92,669,378
- Total 13F value
- $2,241,886,330
- Portfolio coverage rank
- 0%
- Share change
- +5,359,720
- Value change
- +$143,088,730
- Number of holders
- 193
- Shares outstanding
- 85,185,185
- SEC-reported price per share
- $23.48
- Insider filing price
- $23.48
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 61225M102.
- 193 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 189 to 193 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,430,282,358 to $2,241,886,330.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 193 institutions filings for Q2 2026.
Security key
61225M102
Latest holder period
Q2 2026
13F holders
193
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
GLUE full holder history
Monte Rosa Therapeutics, Inc. SEC filings
Monte Rosa Therapeutics, Inc. company facts
Monte Rosa Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61225M102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
GLUE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 10% | +47% | $155,158,528 | +$79,195,063 | 8,876,346 | +104% | Baker Bros. Advisors LP | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 10% | +38% | $214,459,861 | +$102,234,198 | 8,861,282 | +91% | T. Rowe Price Associates, Inc. | 30 Jun 2026 |
| New Enterprise Associates 17, L.P. | 7.9% | -18% | $109,552,918 | -$18,084,463 | 6,692,298 | -14% | New Enterprise Associates 17, L.P. | 01 Jul 2026 |
| Dimension Capital I, L.P. | 8.1% | -6.7% | $107,152,737 | +$13,990,895 | 6,513,765 | +15% | Adam Goulburn | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 6.3% | +6.7% | $88,901,287 | +$21,850,000 | 5,085,886 | +33% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| TCG Crossover GP II, LLC | 5.5% | -24% | $80,795,199 | +$3,398,916 | 4,622,151 | +4.4% | Chen Yu | 31 Mar 2026 |
| Vestal Point Capital, LP | 5.4% | $110,676,000 | 4,600,000 | Vestal Point Capital, LP | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.3% | $20,045,661 | 3,840,165 | BlackRock, Inc. | 31 Dec 2024 | |||
| MONTANOVA CAPITAL, LLC | 4.2% | -22% | $85,401,908 | +$4,560,308 | 3,549,539 | +5.6% | Montanova Capital, LLC | 30 Jun 2026 |
| VANGUARD GROUP INC | 4.8% | -6% | $22,148,142 | -$1,240,441 | 2,988,953 | -5.3% | The Vanguard Group | 30 Sep 2025 |
| Versant Venture Capital VI, L.P. | 3.4% | -34% | $35,080,976 | -$17,220,640 | 2,236,708 | -33% | Versant Venture Capital VI, L.P. | 07 Jan 2026 |
| FMR LLC | 2.8% | $7,072,953 | 1,750,731 | FMR LLC | 30 May 2025 |
As of 30 Jun 2026, 193 institutional investors reported holding 92,669,378 shares of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE). This represents 109% of the company’s total 85,185,185 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
87%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 10% | 8,861,171 | +32% | 0.02% | $214,442,000 |
| NEA Management Company, LLC | 9% | 7,692,298 | 0% | 12% | $186,153,612 |
| BlackRock, Inc. | 8% | 6,843,087 | +21% | 0% | $165,602,706 |
| TCG Crossover Management, LLC | 5.4% | 4,622,151 | 0% | 2.7% | $111,856,054 |
| Vestal Point Capital, LP | 5.4% | 4,600,000 | +28% | 2.6% | $111,320,000 |
| BVF INC/IL | 5.2% | 4,460,886 | 0% | 2.8% | $107,953,441 |
| BAKER BROS. ADVISORS LP | 5.1% | 4,345,736 | 0% | 0.53% | $105,166,811 |
| STATE STREET CORP | 4.4% | 3,731,416 | +11% | 0% | $90,300,267 |
| MONTANOVA CAPITAL, LLC | 4.2% | 3,549,539 | -16% | 1.8% | $85,898,844 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 3,412,927 | +10% | 0% | $82,592,833 |
| Versant Venture Management, LLC | 3.7% | 3,180,780 | 0% | 47% | $76,974,876 |
| BRAIDWELL LP | 2.9% | 2,451,562 | -24% | 2.2% | $59,327,800 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,864,113 | +21% | 0% | $45,121,645 |
| AMERICAN CENTURY COMPANIES INC | 1.9% | 1,622,846 | -42% | 0.02% | $39,272,873 |
| MARSHALL WACE, LLP | 1.9% | 1,593,600 | +11% | 0.03% | $38,565,119 |
| Aisling Capital Management LP | 1.8% | 1,555,664 | 0% | 8% | $37,647,069 |
| Bellevue Group AG | 1.4% | 1,190,000 | -4.8% | 0.61% | $28,798,000 |
| DIMENSIONAL FUND ADVISORS LP | 1.4% | 1,177,488 | +13% | 0.01% | $28,493,337 |
| MPM BIOIMPACT LLC | 1.4% | 1,161,081 | -1.3% | 1.7% | $28,098,160 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.3% | 1,108,295 | -45% | 3% | $26,820,739 |
| Jupiter Topco LLC | 1.3% | 1,072,494 | 0% | 0.01% | $25,965,080 |
| Frazier Life Sciences Management, L.P. | 1.2% | 1,000,000 | 0% | 0.53% | $24,200,000 |
| GOLDMAN SACHS GROUP INC | 1.2% | 998,253 | -0.33% | 0% | $24,157,723 |
| Woodline Partners LP | 1.1% | 962,884 | +1193% | 0.07% | $23,301,793 |
| FMR LLC | 1.1% | 934,414 | -8.8% | 0% | $22,612,829 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
21
Latest
Q2 2026
Rows shown
1-21 of 21
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 92,669,378 | $2,241,886,330 | +$143,088,730 | $24.20 | 193 |
| 2026 Q1 | 86,952,318 | $1,430,282,358 | +$355,307,204 | $16.45 | 189 |
| 2025 Q4 | 64,480,520 | $1,011,031,344 | +$79,666,435 | $15.68 | 161 |
| 2025 Q3 | 60,027,627 | $444,802,878 | -$4,386,129 | $7.41 | 126 |
| 2025 Q2 | 62,196,889 | $280,514,086 | +$11,963,150 | $4.51 | 115 |
| 2025 Q1 | 59,523,717 | $276,191,314 | -$11,913,266 | $4.64 | 105 |
| 2024 Q4 | 60,988,332 | $423,262,031 | +$79,110,231 | $6.94 | 104 |
| 2024 Q3 | 49,754,753 | $263,674,421 | +$18,158,687 | $5.30 | 80 |
| 2024 Q2 | 45,836,316 | $171,427,053 | +$21,976,071 | $3.74 | 73 |
| 2024 Q1 | 39,892,581 | $281,249,822 | -$731,896 | $7.05 | 67 |
| 2023 Q4 | 40,102,427 | $226,575,690 | -$10,023,054 | $5.65 | 71 |
| 2023 Q3 | 42,042,126 | $201,382,486 | +$10,940,133 | $4.79 | 70 |
| 2023 Q2 | 39,734,743 | $272,184,520 | -$3,199,539 | $6.85 | 67 |
| 2023 Q1 | 39,769,032 | $309,801,540 | -$11,077,618 | $7.79 | 69 |
| 2022 Q4 | 41,325,746 | $314,458,629 | +$7,213,706 | $7.61 | 66 |
| 2022 Q3 | 40,353,101 | $329,604,037 | -$3,246,200 | $8.17 | 70 |
| 2022 Q2 | 38,778,221 | $374,994,819 | -$11,927,308 | $9.67 | 56 |
| 2022 Q1 | 39,943,480 | $559,876,587 | +$42,034,475 | $14.02 | 52 |
| 2021 Q4 | 36,340,047 | $741,974,000 | +$28,074,571 | $20.42 | 53 |
| 2021 Q3 | 34,892,057 | $759,420,127 | +$60,728,601 | $22.28 | 54 |
| 2021 Q2 | 32,095,195 | $705,074,000 | +$705,074,000 | $22.70 | 48 |